Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type, and Sales Channel - Global Opportunity Analysis and Industry Forecast, 2021-2025

  • ID: 4603663
  • Report
  • Region: Global
  • 155 pages
  • Allied Analytics LLP
1 of 4
Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, and Selonsertib & Cenicriviroc), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy) - Global Opportunity Analysis and Industry Forecast, 2021-2025

The global non-alcoholic steatohepatitis (NASH) market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.

The nonalcoholic steatohepatitis (NASH) market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.

The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS:

By Drug Type

Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc

By Sales Channel

Hospital Pharmacy
Online Provider
Retail Pharmacy

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED:

Allergan plc. (Tobira Therapeutics)
Cadila Healthcare Limited
Conatus Pharmaceuticals Inc.
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc.
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Novartis International AG
Shire Plc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets, 2021
3.2.2. Top player positioning
3.3. Top winning strategies
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Upsurge in NASH-affected population
3.4.1.2. Rise in prevalence of diabetes & obesity
3.4.1.3. Surge in healthcare expenditures worldwide
3.4.2. Restraints
3.4.2.1. Insufficient diagnostic technologies for NASH
3.4.2.2. Poor demand in the underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Strong presence of pipeline drugs
3.4.3.2. Unmet needs for NASH therapeutics
3.4.3.3. Growth opportunities in the emerging markets
3.4.4. Impact analyses
3.5. Pipeline analyses

CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Vitamin E & pioglitazone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.3. Obeticholic acid
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.4. Elafibranor
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Selonsertib & cenicriviroc
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region

CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.3. Online providers
5.3.1. Market size and forecast, by region
5.4. Retail pharmacy
5.4.1. Market size and forecast, by region

CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S. market size and forecast
6.2.2.2. Canada market size and forecast
6.2.2.3. Mexico market size and forecast
6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany market size and forecast
6.3.2.2. France market size and forecast
6.3.2.3. UK market size and forecast
6.3.2.4. Italy market size and forecast
6.3.2.5. Spain market size and forecast
6.3.2.6. Rest of Europe market size and forecast
6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan market size and forecast
6.4.2.2. China market size and forecast
6.4.2.3. Australia market size and forecast
6.4.2.4. India market size and forecast
6.4.2.5. South Korea market size and forecast
6.4.2.6. Rest of Asia-Pacific market size and forecast
6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil market size and forecast
6.5.2.2. Saudi Arabia market size and forecast
6.5.2.3. South Africa market size and forecast
6.5.2.4. Rest of LAMEA market size and forecast
6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel

CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc (Tobira Therapeutics Inc.)
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Cadila Healthcare Ltd.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.3. Conatus Pharmaceuticals, Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Galmed Pharmaceuticals Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Gemphire Therapeutics Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments
7.6. Genfit SA
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Gilead Sciences, Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Intercept Pharmaceuticals, Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis International AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Shire plc
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Non-Alcoholic Steatohepatitis (NASH) Market, by Drug Type and Sales Channel: Global Opportunity Analysis and Industry Forecast, 20212025," the global non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.

Key Findings of the Non-alcoholic Steatohepatitis (NASH) Market:

Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025.
Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.

North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of NASH along with the increase in prevalence of diabetes & obesity and rise in awareness of NASH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the NASH market in Asia-Pacific region.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll